We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals

145 hedge funds and large institutions have $805M invested in Enanta Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 43 increasing their positions, 64 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

836% more call options, than puts

Call options by funds: $4.12M | Put options by funds: $440K

51% more capital inflows, than outflows

Capital inflows: $97.8M | Capital outflows: $64.8M

2.83% more ownership

Funds ownership: 92.44% → 95.28% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

1% less funds holding

Funds holding: 147 → 145 (-2)

33% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 64

Holders
145
Holders Change
-2
Holders Change %
-1.36%
% of All Funds
2.31%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
43
Reduced
64
Closed
13
Calls
$4.12​M
Puts
$440​K
Net Calls
+$3.68​M
Net Calls Change
-⁠$6.7​M

ENTA Hedge Fund Activity: Q1 2023 in Review

145 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2023, worth a combined $805M — down 10% from $895M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ENTA and 12 opened new positions — a net loss of 1 holder — while 64 trimmed existing stakes and 43 added.

The largest buyer was Braidwell, adding an estimated $34M. The largest seller was State Street, cutting an estimated $14.9M.

  • 145 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2023, down from 147 in Q4 2022.
  • Funds reported $805M of Enanta Pharmaceuticals stock for Q1 2023, down 10% quarter-over-quarter.
  • 12 funds opened new Enanta Pharmaceuticals positions in Q1 2023 and 13 closed out, a net change of -1 holder.
  • The largest Enanta Pharmaceuticals buyer in Q1 2023 was Braidwell, an estimated $34M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2023 was State Street, an estimated $14.9M sold.

Based on aggregated 13F filings for Q1 2023.